By Amy Norton HealthDay Reporter FRIDAY, July 2, 2021 — Racial disparities in breast cancer survival have narrowed in recent years, but Black women with the disease still have double the death rate of white women. That’s according to a study that tracked breast cancer trends in Florida between 1990 and 2015. Overall, deaths from… Read More »
Motherhood is an amazing experience. However, it comes with a lot of responsibilities. If you are a working mom, you have much more on your plate to worry about. In such a situation, you are bound to be concerned about how to pump enough milk for your child in a short period of time. Selecting… Read More »
After Pfizer’s Ibrance failed a crucial study in HR-positive, HR-negative postsurgery breast cancer patients, the company clung to hope that it could still show a benefit in a high-risk subset of those patients. But new data have officially snuffed out those hopes. There’s “no saving adjuvant for Ibrance,” SVB Leerink analyst Geoffrey Porges wrote in… Read More »
A single targeted dose of radiotherapy could be as effective at treating breast cancer as a full course, a long-term study suggests. Researchers said people who received the shorter treatment were also less likely to die of other cancers and heart disease in the following five years. But cancer specialists have raised concerns about the… Read More »
FDA Approves Trodelvy (sacituzumab govitecan-hziy) for Previously-Treated Metastatic Triple Negative Breast Cancer Print this page Morris Plains, N.J., April 22, 2020 — Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy™ (sacituzumab govitecan-hziy) for the treatment… Read More »